This letter discusses using a combination of rolipram, a phosphodiesterase 4 inhibitor, with salbutamol and corticosteroids to treat asthma and bronchial hyperreactivity. It notes that rolipram can inhibit eotaxin-induced eosinophil recruitment and tumor necrosis factor alpha production, and has anti-inflammatory effects. When used with a beta-agonist like salbutamol, it may provide additive benefits through inhibition of antigen-induced contraction and vascular permeability changes involved in allergic diseases. The combination of rolipram, a beta-agonist, and corticosteroids may help treat eosinophilia associated with asthma more effectively than other treatments by blocking eotaxin